‘That Mammogram Saved My Life’: A Busy Mom of Two Says She Missed Her Mammogram Appt, and When She Got the Courage to Reschedule, She Learned She Had Triple-Negative Breast Cancer, an Aggressive Form of the Disease

Albin runs her family’s insurance company, a business passed down for generations. On the day of her scheduled mammogram, work demands pulled her away. “I had a customer come in,” she recalled, explaining how she skipped the appointment. Embarrassed by being a “no-call, no-show,” she delayed rescheduling for months.

Four months later, she finally called her doctor and was able to secure another appointment. That mammogram revealed devastating news: she had triple-negative breast cancer.

WATCH: Understanding Triple-Negative Breast Cancer

Unlike other breast cancers, triple-negative tumors lack three key receptors—estrogen, progesterone, and HER2—which means they don’t respond to hormone therapy or HER2-targeted drugs like Herceptin. Chemotherapy remains the primary treatment option.

“For someone who is newly diagnosed with triple negative breast cancer, most of the time they will need chemotherapy,” medical oncologist Dr. Julie Nangia explained to SurvivorNet.

“Any triple-negative cancer that’s over half a centimeter or has lymph node involvement needs chemotherapy. This is usually two different types of chemotherapy for three months each, with two different classes of drugs. One is called taxanes, and one is called anthracyclines,” Dr. Nangia continued.

WATCH: What Happens During a Double Mastectomy?

“There are different types of breast cancer, and these are defined by biomarkers,” explained Dr. Nangia, medical oncologist at SurvivorNet. “The three biomarkers are estrogen receptor (ER), progesterone receptor (PR), and HER2.”

Albin credits her September 2024 mammogram with saving her life. “If I wouldn’t have gotten my mammogram, I wouldn’t be sitting here today. Mammograms are very, very, very important,” she emphasized.

WATCH: Breast Cancer Survivor Caitlin Kiernam On Life After Reconstruction

Her treatment journey has been extensive: five months of chemotherapy, followed by a double mastectomy and breast reconstruction. Reconstruction, which can involve implants or tissue from other parts of the body, is often described as restoring both physical form and emotional identity. “It’s about putting the cancer in the rearview mirror,” said Dr. Andrea Pusic, chief of Plastic and Reconstructive Surgery at Brigham Health.

Mastectomy decisions vary widely. “Some patients come in wanting both breasts removed right away,” noted Dr. Sarah Cate, Chief of Breast Surgery at Stamford Hospital. “But after reviewing family history, genetic testing, and cancer specifics, many opt for lumpectomy and radiation, which is the standard of care.”

Reflecting on her journey, Albin says the diagnosis affected her entire household. “We all went through cancer—my husband and both of our children,” she shared.

When One Person is diagnosed, the Whole Family Feels It

A serious health diagnosis sends shockwaves far beyond the individual—it touches the lives of every family member. Research published in The Journal of the Royal Society of Medicine found that “most chronic diseases have similar effects on family members [as they do on the patient], including psychological and emotional functioning, disruption of leisure activities, effect on interpersonal relationships, and financial resources.”

Parents, siblings, spouses, and others often carry invisible emotional burdens: “helplessness, lack of control, anger, embarrassment,” researchers observed.

The strain can show up in all kinds of ways—disrupted sleep, altered eating habits, and spiritual or cultural searching for meaning. It can limit freedom, deepen fears about death, and leave loved ones desperately seeking support and understanding.

Yet even amid the emotional toll, experts emphasize that a strong support system has the power to bring families closer. The pain of a diagnosis, while devastating, can also strengthen bonds and foster deeper empathy.

Understanding Your Mammogram Report and Breast Density

A radiologist reading mammograms categorizes breasts into four different categories using the Breast Imaging Reporting and Data System (BI-RADS), a classification system developed by the American College of Radiology (ACR). These include:

• Fatty breast tissue: These breasts are mainly composed of fat with very little dense tissue. Found in less than 10% of women, fatty breasts appear dark on mammograms.
• Scattered fibroglandular breast tissue: These breasts contain a mix of fatty and dense tissue (composed of glands and fibrous tissue). On a mammogram, they have dark areas (fatty tissue) intermixed with light areas (dense tissue). Around 40% of women have breasts that fall in this category.
• Heterogeneously dense breast tissue: This type of breast tissue has many areas of dense tissue and some areas of fat. Found in 40% of women, these breasts look mostly light, with some dark areas on a mammogram.
• Extremely dense breast tissue: Such breasts are almost entirely composed of dense glandular and fibrous connective tissues with very little fat. They are found in 10% of women and appear light on mammograms.

Your breasts are usually called dense on a mammogram report if they fall within the heterogeneously dense breast tissue or the extremely dense breast tissue categories.

Enhanced Screening for Dense Breasts

Women with dense breasts may not know they have it based on feeling alone. Breast density is determined by its appearance on a mammogram. Dr. Connie Lehman, the chief of the Breast Imaging Division at Massachusetts General Hospital, explains to SurvivorNet that fatty breast tissue appears gray on an X-ray. Conversely, dense breast structures appear white during an X-ray. Cancers also appear white on an X-ray, meaning the dense breast structures can mask the possibility of cancer. Luckily, advanced mammograms exist to help doctors navigate this obstacle.

WATCH: 3D Mammograms explained.

“Digital mammography, it turns out, significantly improves the quality of the mammogram…It’s 3D or tomosynthesis mammography,” Dr. Lehman explains.

“This allows us to find more cancers and to significantly reduce our false-positive rate. With digital mammography 3D tomosynthesis, we’re taking thin slices through that breast tissue, like slices of a loaf of bread. We can look at each slice independently rather than trying to see through the entire thickness of the loaf of bread. So those thin slices help us find things that were hidden in all the multiple layers,” Dr. Lehman adds.

Additional testing can be considered for dense breasts, depending on a woman’s personal history, preferences, and her physician’s guidance. These tests include:

• 3-D Mammogram (Breast Tomosynthesis): This technology acquires breast imaging from multiple angles and digitally combines them into a 3D representation of the breast tissue. This allows physicians to see breast tissue architecture better, even in dense breasts. 3D mammograms are fast becoming the standard way of performing mammography.
• Breast Magnetic Resonance Imaging (MRI): An MRI machine uses magnets to create highly detailed, intricate images of the breast. These are mostly reserved for women with an extremely high breast cancer risk. Dense breasts alone may not be a valid reason to obtain a breast MRI. However, dense breasts in women with genetic mutations, like BRCA1 and BRCA2, or a strong family history of breast cancer, could justify obtaining breast MRIs.
• Molecular Breast Imaging (MBI): MBI is a newer imaging technique that uses a radioactive tracer to detect breast cancer. It is beneficial for women with dense breasts. However, MBI is not as widely available as other screening methods.

A new rule from the Food and Drug Administration (FDA) says that facilities offering mammograms must notify patients about their breast tissue density and recommend that they speak with a doctor to determine if further screening is necessary. There will be “uniform guidance” on what language to use and what details to share with the patient to make the communication clear and understandable.

Breast Density Doesn’t Remain the Same Over Time, Impacting Your Cancer Risk

Women with dense breasts are at a higher risk of developing breast cancer. This connection has been demonstrated time and again in several rigorous scientific studies. 1 in 6 women with dense breasts is at risk for breast cancer. Comparatively, 1 in 8 women with average breasts are at risk for this cancer. The exact reason for this difference is not fully understood.

Researchers from Washington University School of Medicine in St. Louis and Brigham and Women’s Hospital in Boston analyzed this connection in a new study.

They recruited 947 women between November 2008 and October 2020. All women were cancer-free at the start of the study and received yearly or biyearly screening mammograms. Researchers tracked the women’s mammogram reports and breast densities over time.

All women experienced a decline in their breast density during the 12 years. Two hundred eighty-nine women developed breast cancer during this time. Those who developed cancer had a lower rate of decrease in breast density than those who did not. The researchers concluded that the rate of breast density changes may indicate future breast cancer risk.

Treating Triple-Negative Breast Cancer

SurvivorNet experts say that triple-negative breast cancer often responds well to chemotherapy. Early stages of this disease (stages 1, 2, or 3) mean that the cancer is confined to the breast and/or lymph nodes that are located right under the arm.

“Our primary line of attack is chemotherapy, and this is regardless of the cancer stage,” medical oncologist Dr. Elizabeth Comen said.

Chemotherapy before you have surgery, also called neoadjuvant therapy, has the primary goal of trying to shrink the tumor before the primary treatment is given, which, in the case of breast cancer, is usually surgery.

WATCH: Undergoing Chemo During Triple-Negative Breast Cancer Treatment

In some cases, doctors may recommend chemotherapy after surgery, also known as adjuvant therapy. This additional treatment may be necessary if there are still cancer cells present, or it might be given to lower the risk that the cancer will come back.

There are different chemotherapy options depending on the burden of disease, which refers to how sick someone is with their disease.

“If the disease burden is not too great, meaning that a woman doesn’t have a lot of symptoms, we can often start with oral chemotherapy,” Dr. Comen explains to SurvivorNet.

“After three months of treatment, we can say, how has the response been, has the disease burden decreased, which is what we hope to see, and ideally, we will continue on that treatment for as long as possible. At some point, a woman may become resistant to the treatment that she’s on, which often means IV chemotherapy is next in line.”

The IV chemotherapy cycle can be two weeks on, one week off, alongside monthly doctor visits.

According to Dr. Heather McArthur, previously medical director of breast oncology at Cedars-Sinai Medical Center, studies suggest that giving these drugs early on in the treatment of metastatic triple-negative breast cancer works better than when taken after chemotherapy.

WATCH: Immunotherapy and Triple Negative Breast Cancer

Clinical trials also suggest that for women with non-metastatic triple-negative breast cancer who received immunotherapy and chemotherapy before surgery, 80 percent of these women had a “pathologically complete response” at the time of surgery, meaning there were no cancer cells left in the breast. These trials led to the approval of Keytruda (pembrolizumab) for the treatment of early-stage triple-negative breast cancer. Keytruda can be used with chemotherapy before surgery and then continued alone after surgery if you are at high risk for your breast cancer returning.

RELATED: Triple-Negative Breast Cancer More Deadly Among Black Women

Genetic Testing to Gauge Triple-Negative Breast Cancer Risk

A research team at Mayo Clinic has identified a group of genes linked to an increased risk of developing triple-negative breast cancer (TNBC)—a discovery that could pave the way for improved screening and earlier detection of this aggressive disease.

“Everybody is nervous about triple-negative breast cancer,” says Dr. Marleen Meyers, a medical oncologist at NYU Perlmutter Cancer Center. “Of all the breast cancers, it’s considered the most aggressive and the most difficult to treat.”

WATCH: Genetic Tests for Triple-Negative Breast Cancer Risk

In the 2018 study involving more than 10,000 people diagnosed with TNBC, researchers found that mutations in five genes—BARD1, BRCA1, BRCA2, PALB2, and RAD51D—were associated with a significantly higher risk of developing the disease. Among Caucasian participants, these mutations also correlated with a greater than 20% lifetime risk for breast cancer overall. Similar patterns were observed in African-American participants.

While this genetic insight is promising, experts caution that only about 10% of breast cancers are hereditary. “Most women who undergo genetic testing won’t test positive for these mutations,” explains Dr. Ophira Ginsburg, Director of the High-Risk Cancer Program at NYU Langone’s Perlmutter Cancer Center.

WATCH: When to Get Genetic Testing?

That’s why genetic testing is typically recommended for women with a strong family history—especially those with relatives who’ve had breast or ovarian cancer, rare cancers, or cancers linked to Lynch Syndrome, a hereditary condition that increases cancer risk. Early identification in these high-risk groups can be critical for prevention and timely treatment.

Breast Cancer Symptoms & Self-Exams

Women are encouraged to do regular self-exams to become familiar with how their breasts feel normally, so when something unusual, like a lump, does form, it can be easily detected. A self-exam includes pressing your fingertips along your breast in a circular motion.

For some women, that means going to their doctor and walking through what a self-breast exam looks like, so they know what normal breast tissue feels like, so if they do feel something abnormal, whether it’s a lump or discharge from the nipple, they know what to ask and what to look for.

Below are common symptoms to look out for:

• New lump in the breast or underarm (armpit)
• Any change in the size or shape of the breast
• Swelling of all or part of the breast
• Skin dimpling or peeling
• Breast or nipple pain
• Nipple turning inward
• Redness or scaliness of the breast or nipple skin
• Nipple discharge (not associated with breastfeeding

When to Screen for Breast Cancer

The medical community has a broad consensus that women should have annual mammograms between the ages of 45 and 54. However, an independent panel of experts called the U.S. Preventive Services Task Force (USPSTF) is saying that women should now start getting mammograms every other year at the age of 40, suggesting that this lowered age for breast cancer screening could save 19% more lives.

The American Cancer Society recommends getting a mammogram every other year for women 55 and older. However, women in this age group who want added reassurance can still get annual mammograms.

WATCH: When you’re getting a mammogram, ask about dense breasts.

Women with a strong family history of breast cancer, a genetic mutation known to increase the risk of breast cancer, such as a BRCA gene mutation, or a medical history, including chest radiation therapy before the age of 30, are considered at higher risk for breast cancer.

Experiencing menstruation at an early age (before 12) or having dense breasts can also put you into a high-risk category. If you are at a higher risk of developing breast cancer, you should begin screening earlier.

Questions For Your Doctor

• What stage is my cancer, and how does that affect my treatment plan?
• What are the recommended chemotherapy options for triple-negative breast cancer, and what side effects should I expect?
• Are there any clinical trials or emerging treatments I should consider?
• How will treatment affect my fertility, physical activity, or ability to work?
• What follow-up care and monitoring will I need after treatment ends

Learn more about SurvivorNet's rigorous medical review process.

---